Login to Your Account



Alteon Suspends Alagebrium Enrollment On Rat Toxicities

By Karen Pihl-Carey


Monday, February 28, 2005
Alteon Inc. voluntarily suspended enrollment in its ongoing Phase II trials of alagebrium after preclinical data indicated high doses of the therapy could be associated with liver cell alterations and tumors. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription